This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people with diabetes and obesity. GLP-1 receptor agonists (RA), such as Ozempic and Mounjaro, were initially designed to help manage blood sugar in type 2 diabetes. Now, they are reshaping the landscape of obesity treatment and metabolic health with impacts that go far beyond the scale. "About 1 in 8 adult Americans has already used GLP-1 drugs. That is 41 million Americans," said Kim Fisher, director of programs at The UC Davis Innovation Institute for Food and Health (IIFH). Recently, the IIFH brought together leading scientists, industry innovators and health care experts to examine how GLP-1-based therapies are transforming obesity and diabetes care. They also discussed what this means for the future of health, food and nutrition. Research is still unraveling how GLP-1 drugs influence the body, from the gut and cardiovascular system to muscular and MedicGLP Support brain function.

What are GLP-1 drugs? GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It helps regulate blood sugar by stimulating insulin, suppressing glucagon, and slowing digestion. Pharmaceutical versions amplify these effects, MedicGLP Supplement reducing appetite and promoting satiety, or a feeling of fullness. For many, this means dramatic weight loss - often 15-20% of body weight - as well as improved blood sugar control. "GLP-1s are ushering in a transformational moment, changing how consumers worldwide eat and live," Justin Siegel, the faculty director of IIFH. GLP-1 has a substantial impact on the gastrointestinal (GI) system. It slows gastric emptying, which helps control blood sugar and prolongs satiety. But the gut is also home to trillions of microbes that influence metabolism. GLP-1 therapies alter the way food moves in the gut and its fermentation patterns. These changes can shift the makeup of the microbiome. "GI intolerance with GLP-1 RA use is a big deal.

Patients might experience nausea, vomiting and even diarrhea. The majority of these symptoms are the effects of GLP-1 RA drugs on the GI tract and the delay in the gastric emptying," said bariatric surgeon Mohamad Ali, professor and chief of Foregut, Metabolic and General Surgery at UC Davis Medical Center. A healthier microbiome supports GLP-1 activity and improves insulin sensitivity. Fiber-rich diets and probiotics may also enhance these effects, reinforcing gut health during therapy. Play video with descriptive audio options. This video may install cookies. Learn more about our privacy policy. GLP-1 signals travel from the gut to the brain via the bloodstream and the vagus nerve. These signals reduce hunger and dampen cravings for high-calorie foods. Emerging research suggests GLP-1 may also affect reward pathways, potentially influencing taste perception. "The patients taking GLP-1 RA medications report that the ‘food noise’ - the constant thinking about food - is quieter," Ali said. Appetite suppression helps with weight loss, but it can also change food preferences.

Patients often report reduced desire for sweets and fatty foods, creating an opportunity to adopt healthier habits. Skeletal muscle is the body’s largest site for glucose uptake and a key player in metabolic health. While GLP-1 drugs promote fat loss, rapid weight reduction can lead to 15-25% lean muscle mass loss. Lean muscle mass is the weight of the body that is not fat - including muscles, bones, organs and more. "We are losing around 20% of muscle mass, but that is not different from diets that restrict calorie intake. Much of the reported 40% lean mass loss with GLP-1 use is coming from the liver," explained exercise physiologist Keith Baar, a professor of Neurobiology, Physiology and Behavior and Physiology and MedicGLP Support Membrane Biology. Losing muscle can lower metabolic rate and physical strength. Strategies like resistance training and high-quality protein intake are essential to maintain muscle during therapy. Bone is metabolically active and responds to incretin hormones, like GLP-1 and GIP, released in the intestines after eating to stimulate the pancreas to produce insulin.